Safety and efficacy of Vildagliptin in real life Chilean diabetic patients

Gonzalo Godoy J,Alejandro Yenes,Vicente Gutiérrez,Mario Montecinos

doi:10.4067/s0034-98872015000100008

Abstract

Vildagliptin is a dipeptidyl peptidase IV inhibitor (DPP4i). Its efficacy and safety of DPP4i in Chilean real life type 2 diabetic (T2D) patients is not well known. To assess the safety profile and effectiveness of 12 weeks of treatment with Vildagliptin for glycemic control in T2D Chilean patients with a poor glycemic control. Retrospective assessment of the effects of Vildagliptin treatment during 12 weeks in 103 T2D patients aged 29 to 92 years (47% males). The main outcomes were changes in glycosylated hemoglobin and the occurrence of adverse effects. After 12 weeks of Vildagliptin use, glycosylated hemoglobin decreased from 8.3 ± 1.4 to 7.2 ± 1.1% (p < 0.01). Fasting plasma glucose and the number of hypoglycemic events also decreased significantly. No significant weight change was observed. The treatment had good compliance, tolerance and patient satisfaction. Vildagliptin treatment reduced glycosylated hemoglobin by 1.1% and was well tolerated in this group of diabetic patients.

Highlights

Safety and efficacy of Vildagliptin in real life Chilean diabetic patients Background: Vildagliptin is a dipeptidyl peptidase IV inhibitor (DPP4i)
Vildagliptin treatment reduced glycosylated hemoglobin by 1.1% and was well tolerated in this group of diabetic patients
En la era de la medicina basada en la evidencia[1], los médicos requieren evaluar los resultados de estudios clínicos controlados usando estudios en condiciones de vida real, que permitan tomar decisiones de prescripción eficaces y con un perfil de seguridad adecuado

Summary

Introduction

Safety and efficacy of Vildagliptin in real life Chilean diabetic patients Background: Vildagliptin is a dipeptidyl peptidase IV inhibitor (DPP4i). Evalúa en vida real el control glicémico, seguridad y tolerancia de vildagliptina, en pacientes con diabetes mellitus tipo 2 (DMT2) chilenos, que no habían logrado buen control glicémico con dieta y/o ejercicio y/o uno o dos hipoglicemiantes orales de otra clase.

Objectives

Results

Conclusion